ArticleDiabetes, obesity & metabolism2025
Dynamic phenotypes of preclinical and clinical obesity in relation to new-onset cancer risk: A longitudinal analysis from the UK biobank.
Article in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- The Clinical Outcomes of Preclinical and Clinical Obesity Across Multiple Cohorts.Obesity (Silver Spring, Md.) · 2026Article
- Beyond BMI: The Impact of the New Lancet Commission Diagnostic Criteria on Prevalence of Obesity in the United States.Obesity (Silver Spring, Md.) · 2026Article
- If treating obesity with GLP-1-based therapies protects the heart, could it also prevent cancer or improve cancer outcomes? The case for randomized trials.Diabetes, obesity & metabolism · 2026Article
- Long-term impact of newly-proposed clinical obesity on autoimmune disease incidence: insights from the UK Biobank.International journal of obesity (2005) · 2026Article
- Handgrip Strength and Trajectories of Preclinical Obesity Progression: A Multistate Model Analysis Using the UK Biobank.The Journal of clinical endocrinology and metabolism · 2026Article
- Correspondence regarding "excess adiposity and cancer: evaluating a preclinical-clinical obesity framework for risk stratification".EClinicalMedicine · 2025Article
- Contributions of Clinical Obesity and Preclinical Obesity to the All-Cause Mortality Risk: Findings From the UK Biobank Cohort.Diabetes/metabolism research and reviews · 2025Article
- Dynamic phenotypes of preclinical and clinical obesity in relation to new-onset cancer risk: A longitudinal analysis from the UK biobank.Diabetes, obesity & metabolism · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimThe definition of clinical obesity was newly announced. Our study aims to investigate the relationship between different states of obesity and dysfunctions due to obesity with cancer incidence and mortality.
methodsThe prospective cohort study from the UK Biobank included 220 016 participants. Anthropometric parameters, in combination with obesity-induced dysfunctions, were used to diagnose clinical obesity. Six clusters were categorized according to individual's baseline and follow-up dysfunction status. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for cancer incidence risk were estimated using the landmark analysis.
resultsAfter a mean follow-up period of 11.0 years, a total of 24 066 cancer incidence was observed. Using Cluster 1 (participants without obesity and dysfunction at baseline and during follow-up) as the reference group, Cluster 5 (preclinical obesity with follow-up dysfunctions; HR = 3.17, 95% CI: 3.05-3.29) exhibited the highest multivariable-adjusted cancer incidence risk, while Cluster 4 (preclinical obesity without follow-up dysfunctions; HR = 0.88, 95% CI: 0.85-0.92) showed the lowest. Additionally, the fully adjusted HRs for cancer mortality showed the highest in Cluster 6 (clinical obesity; HR = 1.82, 95% CI: 1.65-2.00), compared with Cluster 1. Site-specific analyses showed consistently higher cancer risks in Cluster 5 and 6 across various types of cancer, notably the incidence of pancreatic cancer and the mortality of prostate or bladder cancer.
conclusionObesity-induced dysfunction was significantly associated with cancer risk. For future clinical practice, the early identification and intervention of clinical obesity and obesity-induced dysfunctions are of critical importance for reducing cancer risks.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.